Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06034743 · ClinicalTrials.gov registry record · Phase 3

A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

A Phase 3 study of Uncontrolled Hypertension and Resistant Hypertension, sponsored by AstraZeneca.

Completed
Registry status
Phase 3
Development phase
796
Enrollment target
20
Study locations

NCT06034743 is a Phase 3 study of Uncontrolled Hypertension and Resistant Hypertension that has completed, run by AstraZeneca. The registered enrollment target is 796 participants, above the 685-participant average among 10 other Uncontrolled Hypertension trials with a reported enrollment target (16% higher). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06034743, a Phase 3 study of Uncontrolled Hypertension and Resistant Hypertension, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 3
Development phase
796 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase III, multicentre, randomised, double-blinded, placebo-controlled, parallel group study to evaluate the safety, tolerability and effect of 1 or 2 mg baxdrostat versus placebo, administered once daily (QD) orally, on the reduction of systolic blood pressure in approximately 720 participants aged ≥ 18 years with hypertension, despite a stable regimen of 2 antihypertensive agents at baseline, one of which is a diuretic (uncontrolled hypertension); or ≥ 3 antihypertensive agents at baseline, one of which is a diuretic (treatment-resistant hypertension).

Conditions Studied

Uncontrolled Hypertension Resistant Hypertension

Interventions

  • DRUG Placebo
  • DRUG Baxdrostat

Study Locations (20)

California

  • Research Site - Fresno
  • Research Site - Lincoln
  • Research Site - Orange
  • Research Site - Rancho Cucamonga
  • Research Site - Stanford

Arizona

  • Research Site - Scottsdale
  • Research Site - Sun City West
  • Research Site - Surprise

Florida

  • Research Site - Clearwater
  • Research Site - Jacksonville
  • Research Site - Port Orange

Georgia

  • Research Site - Atlanta
  • Research Site - Decatur

Alabama

  • Research Site - Saraland

Arkansas

  • Research Site - Little Rock

Connecticut

  • Research Site - New Haven

Illinois

  • Research Site - Springfield

Trial Details

FieldValue
Enrollment Target 796 participants
Start Date 2023-11-22
Est. Completion 2025-10-10
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06034743

The ClinicalTrials.gov registry entry for NCT06034743 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 796 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 685-participant average among 10 other Uncontrolled Hypertension trials with a reported enrollment target (16% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Uncontrolled Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06034743 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Arizona, Florida.

Frequently Asked Questions

What is clinical trial NCT06034743 about?

NCT06034743 is a clinical study titled "A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension". This is a Phase III, multicentre, randomised, double-blinded, placebo-controlled, parallel group study to evaluate the safety, tolerability and effect of 1 or 2 mg baxdrostat versus placebo, administered once daily (QD) orally, on the reduction of systolic blood pressure in approximately 720 partici...

What is the current status of trial NCT06034743?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 796 participants. The study started on 2023-11-22. Estimated completion is 2025-10-10.

What conditions does trial NCT06034743 study?

This clinical trial studies the following conditions: Uncontrolled Hypertension, Resistant Hypertension.

What interventions are being tested in trial NCT06034743?

The interventions under investigation include: Placebo (DRUG), Baxdrostat (DRUG).

Who is sponsoring clinical trial NCT06034743?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06034743 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Uncontrolled Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Uncontrolled Hypertension

All registered trials for this condition

Resistant Hypertension

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.